Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Studies of liver transplant patients off anti-rejection drugs have altered cell profile

03.06.2003


University of Pittsburgh researchers report results in American Journal of Transplantation and at American Transplant Congress, suggesting blood test to determine who can be weaned not far off



Liver transplant patients who are off all immunosuppression and those who are undergoing withdrawal of their anti-rejection drugs have higher concentrations of a special immune system cell than those patients who have failed attempts at weaning or who have a history of organ rejection, report University of Pittsburgh researchers. Those off drugs have the same cellular profile as normal, healthy volunteers, who the researchers also studied.

Results of the study are published in the June issue of the American Journal of Transplantation and are being presented today at the American Transplant Congress, the joint scientific meeting of the American Society of Transplant Surgeons and the American Society of Transplantation running through June 4 at the Marriott Wardman Park Hotel in Washington, D.C.


The researchers hope the findings will bring them one step closer to developing a simple blood test predictive of transplant tolerance – the immune system’s full acceptance of a transplanted organ – and of which patients can be successfully weaned off all drugs. However, the researchers caution that further studies will be needed to verify their results.

"Developing such a test or series of tests would be of considerable value in identifying those patients who might be safely weaned off anti-rejection therapy. Our finding a higher incidence of a subtype of a certain dendritic cell in our weaned and nearly weaned patients is a positive step toward this goal," said lead author George Mazariegos, M.D., associate professor of surgery at the Thomas E. Starzl Transplantation Institute and the University of Pittsburgh School of Medicine.

Looking for the presence of different kinds of dendritic cells, the researchers found that patients off all anti-rejection drugs and those in the process of drug withdrawal had significantly more of a beneficial kind of dendritic cell and fewer numbers of the more harmful dendritic cells, a cellular profile that was similar to normal, healthy non-transplant patients who served as a control group. Compared to those who required daily doses of anti-rejection drugs – those who failed at being weaned or who had a history of rejection episodes – the patients off drugs or nearing that target also had a much higher ratio of the good cells to bad cells.

These so-called beneficial dendritic cells are immature or precursor dendritic cells that derive from plasmacytoid T cells (pDC2). While dendritic cells, a rare type of white blood cell that is present in all tissues, are usually known for their ability to identify and present antigens, or foreign substances, to other immune system cells that are programmed to destroy the antigen, not until recently did researchers identify subtypes like the pDC2 that have the opposite effect. These appear to regulate the immune response and determine that a frontline attack against the organ by T cells is unwarranted. "It is quite exciting to identify the presence of this dendritic cell subtype, which we have noted in laboratory models, in patients who by virtue of their being off immunosuppression are tolerant of their transplanted organs," stated Angus Thomson, Ph.D., D.Sc., professor of surgery and immunology at the Thomas E. Starzl Transplantation Institute and University of Pittsburgh School of Medicine, and senior author.

The published pilot study involved six patients who had been weaned for a mean of 3.3 years, the longest for nearly eight years. Of these, two had been weaned through a physician-controlled protocol, three were taken off the drugs because of serious infectious disease concerns, and one patient had stopped taking the drugs on his own. A second group of patients consisted of 23 patients undergoing the weaning process, and the third group was comprised of 11 patients taking maintenance doses of immunosuppression. Six of these 11 had failed at weaning and five had a history of rejection episodes. Thirteen healthy non-transplant patients served as controls.

At ATC, Dr. Mazariegos is reporting update results that were obtained in eight weaned patients, 26 patients in the process of being weaned and 16 patients who required maintenance immunosuppression. Of the weaned patients, three were taken off for emergent reasons, three were weaned through the protocol and two were noncompliant patients who stopped on their own.

According to the authors, their findings involving dendritic cells, and those published by the team last year that looked at genetic profiles of key regulatory proteins that regulate the immune system, are the first to definitively give clues to the make-up of patients who are able to be off all immunosuppression.

"While the initial results indicate there may be some correlation with the presence of ’good dendritic cells’ and immune unresponsiveness, a longer, more complete investigation must now be performed if these cells are to be validated as a surrogate marker of tolerance," said Terry Strom, M.D., co-chair of the Immune Tolerance Network (ITN) Assay Group.

To determine the validity of the dendritic cell profile as a possible test to predict successful weaning, the researchers plan to examine a larger group of liver transplant patients in whom weaning is being considered.

Typically, a life-long regimen of anti-rejection drugs is required to prevent the transplanted organ from being attacked by the patient’s immune system. Such drugs can cause serious complications, such as tumor growth, and make patients more susceptible to infections. The risks associated with long-term immunosuppressive therapies are one of the key limiting factors of successful organ transplantation.

This study was performed as a project of the ITN, a seven-year clinical research project headquartered at the University of California, San Francisco and supported by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation.

Dr. Thomson is principal investigator of the Pittsburgh-based ITN study and Dr. Mazariegos is a co-investigator. Other researchers include Adriana Zeevi, Ph.D., co-principal investigator, and Jorge Reyes, M.D., a co-investigator.


CONTACT:
Lisa Rossi (cell 412-916-3315)
Michele Baum
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
RossiL@upmc.edu
BaumMD@upmc.edu

Lisa Rossi | EurekAlert!
Further information:
http://www.upmc.edu/

More articles from Health and Medicine:

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Previous evidence of water on mars now identified as grainflows

21.11.2017 | Physics and Astronomy

NASA's James Webb Space Telescope completes final cryogenic testing

21.11.2017 | Physics and Astronomy

New catalyst controls activation of a carbon-hydrogen bond

21.11.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>